Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11-February 2024-www.financetom.com

Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Incyte Gets FDA Approval for Opzelura in Children Aged 2 to 11

Sep 20, 2025 9:29 PM

05:07 PM EDT, 09/18/2025 (MT Newswires) -- Incyte ( INCY ) said late Thursday the US Food and Drug Administration has approved the use of Opzelura cream to treat mild to moderate atopic dermatitis in non-immunocompromised children aged 2 to 11.

The milestone marks the third US approval for Opzelura, it said.

Previous page： Market Chatter: Vanguard Says Fed's Caution Will Hold Back Canada On Rate Cuts Next page： Mustang Bio Shares Rise After Company Says CAR-T Therapy Indicates 90% Response Rate in WM Blood Cancer Trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Vanguard Says Fed's Caution Will Hold Back Canada On Rate Cuts

Jun 17, 2024

09:28 AM EDT, 06/17/2024 (MT Newswires) -- The Bank of Canada may hesitate to make aggressive rate cuts until policymakers feel assured the U.S. Federal Reserve is ready to start lowering borrowing costs, Vanguard Group economist Roger Aliaga-Diaz said, Bloomberg News is reporting on this Monday. The report noted Fed policymakers last week shifted their forecasts for the path of...

Mustang Bio Shares Rise After Company Says CAR-T Therapy Indicates 90% Response Rate in WM Blood Cancer Trial

Jun 17, 2024

09:29 AM EDT, 06/17/2024 (MT Newswires) -- Mustang Bio ( MBIO ) shares were up nearly 195% in recent Monday premarket activity after the company said that updated data from its phase 1/2 clinical trial of MB-106 indicated a 90% overall response rate in Waldenstrom macroglobulinemia blood cancer patients previously treated with Bruton's tyrosine kinase inhibitors. The company said that...

Marsh & McLennan's Oliver Wyman to Acquire Veritas Total Solutions

Jun 17, 2024

09:28 AM EDT, 06/17/2024 (MT Newswires) -- Marsh & McLennan Companies' ( MMC ) Oliver Wyman has entered into an agreement to acquire Veritas Total Solutions, a commodity trading advisory company, in a deal slated to close in Q3, Oliver Wyman said. Financial terms were not disclosed. ...

Itron Launching Private Offering of $500 Million Convertible Senior Notes

Jun 17, 2024

09:28 AM EDT, 06/17/2024 (MT Newswires) -- Itron ( ITRI ) said Monday it plans to launch a private offering of $500 million of convertible senior notes due 2030, subject to market conditions. Initial buyers of the notes will be given the option to buy an additional $75 million of the notes, the company said, adding the terms of the...